Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: Validation and application of a new analytical method to monitor treatment compliance

Revista Brasileira de Hematologia e Hemoterapia

Volumn 35, Issue 2, 2013, Pages 103-108

  Rezende, Vinícius Marcondes ^a   Rivellis, Ariane Julio ^a   Gomes, Melissa Medrano ^a   Dörr, Felipe Augusto ^a   Novaes, Mafalda Megumi Yoshinaga ^a   Nardinelli, Luciana ^a   Costa, Ariel Lais de Lima ^a   Chamone, Dalton de Alencar Fisher ^a   Bendit, Israel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antineoplastic agents administration Dosage; BCR ABL positive; Chromatography; Chronic; High pressure liquid; Leukemia; Mass spectrometry; Myelogenous; Pyrimidines administration Dosage; Therapeutic drug monitoring

Indexed keywords

EID: 84879064661     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.5581/1516-8484.20130030     Document Type: Article

References (27)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417. Comment in: N Engl J Med. 2007;356(17):1780; author reply 1780.
2. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18(8):1321-1331.
3. Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res. 2007;13(4):1089-1097.
4. Nardelli J, Sanabani SS, Didone A, Ferreria P de B, Serpa M, Novaes MM, et al. Pretheraputic expression of hoct1 gene predict a complete molecular response to imatinib mesylate in chronic myeloid leukemia chronic phase. Acta Haematol. 2012;127(4):228-234.
5. White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, et al. Functional activity of the oct-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010;28(16):2761-7.
6. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, et al. Pharmacokinetics and Pharmacodynamics of imatinib in a phase i trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22(5):935-942.Comment in: J Clin Oncol. 2005;23(16):3855-6; author reply 3857-8.
7. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R; European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-1820.
8. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European leukemiaNet. J Clin Oncol. 2009;27(35):6041-6051. Comment in: J Clin Oncol. 2010;28(18):e310; author reply e311.
9. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109(8):3496-3499. Comment in: Blood. 2007;110(5):1699-1701; author reply 1701.
10. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111(8):4022-4028.
11. Awidi A, Salem II, Najib N, Mefleh R, Tarawneh B. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison. Leuk Res. 2010;34(6):714-717.
12. Parise RA, Ramanathan RK, Hayes MJ, Egorin MJ. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791(1-2):39-44.
13. Roth O, Spreux-Varoquaux O, Bouchet S, Rousselot P, Castaigne S, Rigaudeau S, et al. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS. Clin Chim Acta. 2010;411(3-4):140-146.
14. Davies A, Hayes AK, Knight K, Watmough SJ, Pirmohamed M, Clark RE. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk Res. 2010;34(6):702-707.
15. Mičová K, Friedecký D, Faber E, Polýnková A, Adam T. Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma. Clin Chim Acta. 2010;411(23-24):1957-1962.
16. Titier K, Picard S, Ducint D, Teilhet E, Moore N, Berthaud P, et al. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2005;27(5):634-640. Erratum in: Ther Drug Monit. 2005;27(6):810.
17. Solassol I, Bressolle F, Philibert L, Charasson V, Astre C, Pinguet F. Liquid chromatography-electrospray mass spectrometry determination of imatinib and its main metabolite, N-desmethyl-imatinib in human plasma. J Liquid Chromat Related Technol. 2006;29(17/20): 2957-2974.
18. Bakhtiar R, Khemani L, Hayes M, Bedman T, Tse F. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2002;28(6):1183-1194.
19. Miura M, Takahashi N, Sawada KI. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection. J Chromatogr Sci. 2011;49(5):412-415.
20. Brasil. Agência Nacional de Vigilância Sanitária (ANVISA). Resolução RE no 899, de 29 de maio de 2003. Guia para validação de métodos analíticos e bioanalíticos Brasília: ANVISA; 2003. Available from: http://portal.anvisa.gov.br/wps/wcm/connect/4983b0004745975da005f43fbc4c6735/RE_899_2003_Determina+a+publica%C3%A7%C3%A3o+do+Guia+para+valida%C3%A7%C3%A3o+de+m%C3%A9todos+anal%C3%ADticos+e+bioanal%C3%ADticos.pdf?MOD=AJPERES.
21. Food and Drug Administration (FDA). Guidance for industry: bioanalytical method validation. Bethesda: FDA: 2001. Available from: http://www.fda.gov/downloads/Drugs/./Guidances/ucm070107.pdf.
22. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.Comment in: Blood. 2007;109(5):2263; author reply 2263-4.
23. Vessman J, Stefan RI, Staden JF, Danzer K, Lindner W, Burns DT, et al. Selectivity in analytical chemistry (IUPAC Recommendations 2001). Pure Appl Chem.;73(8):5.
24. Teng JF, Mabasa VH, Ensom MH. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit. 2012;34(1):85-97.
25. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003;102(1):83-86.
26. Guilhot F, Hughes T, Cortes J, Druker BJ, Baccarani M, Gathmann I, et al. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 2012;97(5):731-738.
27. Guilhot F, Roy L, Tomowiak C. Current treatment strategies in chronic myeloid leukemia. Curr Opin Hematol. 2012;19(2):102-109.